On October 9, 2025, Sunshine Biopharma Inc. announced the development of a new series of orally active, non‑covalent protease inhibitors that demonstrate dose‑dependent antiviral activity in mice infected with SARS‑CoV‑2.
The compounds were developed in partnership with the University of Arizona as part of an ongoing collaboration, and they target the viral protease enzyme essential for SARS‑CoV‑2 replication. The inhibitors are orally active, offering a potential advantage over existing protease inhibitors that require intravenous administration.
The preclinical data show that the inhibitors reduce viral load in infected mice in a dose‑dependent manner, indicating strong antiviral potency.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.